Holen Sie sich die Stockscreener-App
1.01
8.18%
-0.09
Handel nachbörslich:
1.06
0.05
+4.95%
Schlusskurs vom Vortag:
$1.10
Offen:
$1.08
24-Stunden-Volumen:
795.48K
Relative Volume:
0.15
Marktkapitalisierung:
$19.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-33.04M
KGV:
-0.111
EPS:
-9.1023
Netto-Cashflow:
$-39.66M
1W Leistung:
-12.17%
1M Leistung:
-17.89%
6M Leistung:
-97.48%
1J Leistung:
-91.51%
1-Tages-Spanne:
$1.01
$1.09
1-Wochen-Bereich:
$1.00
$1.1889
52-Wochen-Spanne:
$0.79
$45.50
Quince Therapeutics Inc Stock (QNCX) Company Profile
Firmenname
Quince Therapeutics Inc
Sektor
Branche
Telefon
415-910-5717
Adresse
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Compare QNCX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.01 | 21.52M | 0 | -33.04M | -39.66M | -9.1023 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-08-05 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-03-24 | Eingeleitet | Oppenheimer | Outperform |
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - Insider Monkey
QNCX Stock Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
5 Popular Penny Stocks on Robinhood to Watch in 2026 - Insider Monkey
Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN
Quince Therapeutics Inc. (QNCX) Q1 2026 Earnings: Surprise Profitability as EPS Beats Estimates by Over 200% - thelegaladvocate.com
Deal Watch: Quince Moves Into Inhaled Respiratory Disease With Orphai Acquisition - Citeline News & Insights
Quince Therapeutics regains compliance with Nasdaq listing requirements By Investing.com - Investing.com South Africa
Quince Therapeutics regains compliance with Nasdaq listing requirements - Investing.com
Quince regains Nasdaq compliance after reporting $15.7M stockholders' equity - TradingView
[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan
Time is ripe for Quince with Orphai buy and $187m financing - The Pharma Letter
QNCX Stock Price, Quote & Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill
Quince Therapeutics (QNCX) Expands Pipeline with Acquisition of - GuruFocus
Quince Therapeutics (QNCX) Reveals Positive Phase 2a Results for LAM-001 - GuruFocus
Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics IncM&A CallSlideshow (NASDAQ:QNCX) 2026-05-18 - Seeking Alpha
LAM-001 trial shows gains in PH-ILD patients for Quince Therapeutics (QNCX) - Stock Titan
Quince reports phase 2a data for LAM-001 in lung disease By Investing.com - Investing.com Australia
QNCX Stock Slides As Traders React To Volatile Price Action - StocksToTrade
Quince acquires Orphai, raises $115M in private placement - Investing.com UK
Quince reports phase 2a data for LAM-001 in lung disease - Investing.com UK
Quince Therapeutics reports phase 2a data for LAM-001 in PH-ILD By Investing.com - Investing.com South Africa
Quince acquires Orphai, raises $115M in private placement By Investing.com - Investing.com South Africa
Quince Therapeutics announces LAM-001 data - TipRanks
Quince Therapeutics Closes Orphai Deal and Secures Funding - TipRanks
QNCX: Acquisition and financing secure LAM-001’s development for rare pulmonary diseases through 2028 - TradingView
UPDATEQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - The Manila Times
Quince announces acquisition of Orphai and up to $187 million private placement to advance pulmonary pipeline - marketscreener.com
Quince Therapeutics Acquires Orphai and Secures $187M Financing to Advance Pulmonary Rapamycin Pipeline - Minichart
Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - The Manila Times
Quince Therapeutics reports phase 2a data for LAM-001 in PH-ILD - Investing.com Canada
Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing - TechStock²
Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPE - Stock Titan
Press Release: Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - Moomoo
Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - marketscreener.com
QNCX Stock Slides As Traders Weigh Cash Runway And Volatility - timothysykes.com
Quince Therapeutics, Inc. acquired OrphAI Therapeutics Inc for $80.9 million. - marketscreener.com
Quince Therapeutics, Inc. announced that it expects to receive $115.000298 million in funding - marketscreener.com
QNCX Should I Buy - Intellectia AI
Nantahala Capital (QNCX) reports 4.53M shares, 7.52% stake disclosed - Stock Titan
Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60 - MSN
Quince Therapeutics stock (US74833Q1004): Analysts see 345% upside potential - AD HOC NEWS
Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80 - MSN
TradingKey - TradingKey
QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings - Moomoo
Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Trial setback and cash strain shape Quince (NASDAQ: QNCX) Q1 update - Stock Titan
Quince Therapeutics Inc expected to post a loss of $2.56 a shareEarnings Preview - TradingView
Finanzdaten der Quince Therapeutics Inc-Aktie (QNCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.13%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):